Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua A Parrish

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
JAMA Network Open|November 15, 2024
Racial and Ethnic Differences in Prostate Cancer Epidemiology Across Disease States in the VAShannon R Stock, Michael T Burns, Justin Waller, et al.
Urologic Oncology|April 5, 2026
Costs of care and oncologic outcomes associated with blue light cystoscopy in an equal access setting: Results from the BRAVO studyAli A Nasrallah, Claire Evans, Lin Gu, et al.
Cancer Medicine|December 21, 2025
Integrating NLP to Enhance Algorithmic Identification of Metastatic and Castration-Resistant Prostate Cancer in Large Claims-Based StudiesShannon R Stock, Joshua A Parrish, Michael T Burns, et al.
Prostate Cancer and Prostatic Diseases|July 24, 2025
Survival benefit associated with first-line androgen receptor pathway inhibitors for de novo metastatic castration-sensitive prostate cancerStephen J Freedland, Agnes Hong, Nader El-Chaar, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
JAMA Network Open|November 15, 2024
Racial and Ethnic Differences in Prostate Cancer Epidemiology Across Disease States in the VAShannon R Stock, Michael T Burns, Justin Waller, et al.
Urologic Oncology|April 5, 2026
Costs of care and oncologic outcomes associated with blue light cystoscopy in an equal access setting: Results from the BRAVO studyAli A Nasrallah, Claire Evans, Lin Gu, et al.
Cancer Medicine|December 21, 2025
Integrating NLP to Enhance Algorithmic Identification of Metastatic and Castration-Resistant Prostate Cancer in Large Claims-Based StudiesShannon R Stock, Joshua A Parrish, Michael T Burns, et al.
Prostate Cancer and Prostatic Diseases|July 24, 2025
Survival benefit associated with first-line androgen receptor pathway inhibitors for de novo metastatic castration-sensitive prostate cancerStephen J Freedland, Agnes Hong, Nader El-Chaar, et al.
Pageof 1